Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04802837 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
A Phase 3 study, sponsored by Summit Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT04802837 is a Phase 3 study that was terminated before completion, run by Summit Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT04802837, a Phase 3 study, was terminated before completion, sponsored by Summit Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
Interventions
- DRUG Vancomycin
- DRUG Ridinilazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04802837
The ClinicalTrials.gov registry entry for NCT04802837 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Summit Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT04802837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04802837 about?
NCT04802837 is a clinical study titled "Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects". Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
What is the current status of trial NCT04802837?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2021-05-19. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT04802837?
The interventions under investigation include: Vancomycin (DRUG), Ridinilazole (DRUG).
Who is sponsoring clinical trial NCT04802837?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.